After taking a $73M hit, J&J partner Genmab loses arbitration over royalties on megablockbuster Darzalex
J&J has won an arbitration against Genmab on two matters related to their licensing pact for daratumumab, the antibody perhaps better known under the megablockbuster multiple myeloma brand Darzalex.
The longtime partnership — and the royalty stream that comes with it — with J&J’s Janssen has been crucial for the Copenhagen-based biotech. But Janssen began reducing its royalty payments in 2020, prompting Genmab to seek legal clarification of the exact amount of royalties it’s entitled to.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.